in 2018, AD is the 6th leadingcause of death in the USA.
Currently 5.7 millionAmericans are living with AD
Americans are expected tolive with AD by 2050
Out of the top ten deadliestdiseases, AD is the onlyone that remains without amethod of prevention, cureor modification.
The prevalence of Alzheimer’s Disease (AD) is increasing at an alarming rate. According to the Alzheimer’s Association, in 2018, AD is the 6th leading cause of death in the United States. Currently 5.7 million Americans are living with AD, and by 2050, this figure is expected to rise to nearly 14 million. Out of the top ten deadliest diseases, AD is the only one that remains without a method of prevention, cure or modification.
Neuronix has taken an innovative approach to the treatment of AD. As opposed to a pharmaceutical platform, Neuronix has developed the first and only medical device for treatment of AD. Its patented device is called the neuroADTM Therapy System and combines two treatment modalities- Repetitive Transcranial Magnetic Stimulation (TMS) and Cognitive Training (CgT). Each modality has been researched independently, yet neither has been proven to deliver long-term results. Neuronix is the first company to combine the two (patent protected technology), producing a synergistic effect that delivers measurable, long-term improvements in the ognitive, behavioral and functional capabilities of patients with mild to moderate AD.
- Proven, safe and effective
- Non-invasive treatment
- Adjunctive to existing medications
- Minimal side effects
For nearly a decade, Neuronix has performed clinical studies which have validated the safety and effectiveness of its solution. The studies have used both ADAS-Cog and ADCS-CGIC tests to evaluate the efficacy of the treatment. Neuronix’s US pivotal, multi-center study showed a positive and statistically significant difference of -1.8 points in ADAS-Cog between the Active Group and Sham Group, and a 0.45 difference in ADCS-CGIC at 12 weeks follow-up.
These results and those of other studies have been presented in Peer Reviewed Publications and showcased in international conferences. Furthermore, Neuronix’s Scientific Advisory Board consists of renowned experts in the field of AD who have guided the company throughout its research.
While the neuroADTM treatment does not cure AD, it has been shown to improve the cognition and functional/behavioral capabilities of patients suffering from AD on top of Standard of Care treatment. Small scale studies have shown that the treatment results may last between six months to two years. The treatment can be safely administered in conjunction with current Alzheimer’s drug therapies, whereby side-effects or pain are mild and rare, and resolve spontaneously.
The neuroADTM Therapy System has received CE mark approval and is currently available in select centers in Europe, Asia and Australia.
The device is pending FDA clearance in the United States.